2015;180:246-254. 134. Wang KL, Lip GY, Lin SJ, Chiang CE. Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial brillation: meta-analysis. Stroke. 2015;46(9): 2555-2561. 135. Chan YH, Yen KC, See LC, et al. Cardiovascular, bleeding, and mortality risks of dabigatran in Asians with nonvalvular atrial brillation. Stroke. 2016;47(2):441-449. 136. Chan YH, Kuo CT, Yeh YH, et al. Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial brillation. J Am Coll Cardiol. 2016;68(13):1389- 1401. 137. Fredenburgh JC, Gross PL, Weitz JI. Emerging anticoagulant strategies. Blood. 2017;129(2):147-154. 138. van Montfoort ML, Meijers JC. Recent insights into the role of the contact pathway in thrombo-in ammatory disorders. Hematol Am Soc Hematol Educ Program. 2014;2014(1):60-65. 139. Gailani D. Future prospects for contact factors as therapeutic targets. Hematol Am Soc Hematol Educ Program. 2014;2014(1):52- 59. 140. Buller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372(3):232-240. 141. National Institutes of Health Clinical Center. NCT02553889. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT02553889. 142. Van de Werf F, Brueckmann M, Connolly SJ, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J. 2012;163(6): 931-937 e931. 143. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;110(6):1087-1107. 144. Holbrook A, Schulman S, Witt DM, et al. 